These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23379343)

  • 21. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trials of HIV vaccines.
    Graham BS
    Annu Rev Med; 2002; 53():207-21. PubMed ID: 11818471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV vaccines in infants and children.
    Lambert JS
    Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine development against HIV-1: current perspectives and future directions.
    Edgeworth RL; San JH; Rosenzweig JA; Nguyen NL; Boyer JD; Ugen KE
    Immunol Res; 2002; 25(1):53-74. PubMed ID: 11868934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling HIV vaccine trials of the future.
    Gilbert PB; Huang Y; Janes HE
    Curr Opin HIV AIDS; 2016 Nov; 11(6):620-627. PubMed ID: 27662407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines.
    Ferrantelli F; Cafaro A; Ensoli B
    Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.
    Staprans SI; Feinberg MB
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S5-32. PubMed ID: 15285703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Criteria for selection of HIV vaccine candidates--general principles.
    Ensoli B
    Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational vaccine strategies against AIDS: background and rationale.
    Ensoli B
    Microbes Infect; 2005 Nov; 7(14):1445-52. PubMed ID: 16213183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.
    Janes H; Gilbert P; Buchbinder S; Kublin J; Sobieszczyk ME; Hammer SM
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1513-23. PubMed ID: 23597282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccine development: past, present and future.
    Robb ML
    IDrugs; 2010 Dec; 13(12):852-6. PubMed ID: 21154142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design.
    Tobin SC
    AIDS; 2015 Sep; 29(15):N13. PubMed ID: 26237101
    [No Abstract]   [Full Text] [Related]  

  • 35. HIV vaccines: lessons learned and the way forward.
    Kim JH; Rerks-Ngarm S; Excler JL; Michael NL
    Curr Opin HIV AIDS; 2010 Sep; 5(5):428-34. PubMed ID: 20978385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.
    Ferrantelli F; Buttò S; Cafaro A; Wahren B; Ensoli B
    Springer Semin Immunopathol; 2006 Nov; 28(3):289-301. PubMed ID: 16983452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling immunity to HIV vaccines with systems biology.
    Andersen-Nissen E; Heit A; McElrath MJ
    Curr Opin HIV AIDS; 2012 Jan; 7(1):32-7. PubMed ID: 22134340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials.
    Klein M
    Vaccine; 2001 Mar; 19(17-19):2210-5. PubMed ID: 11257335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.